Down syndrome and Alzheimer disease: Response to donepezil

Archives of Neurology

Volumn 59, Issue 7, 2002, Pages 1133-1136

  Lott, Ira T ^a   Osann, Kathryn ^a   Doran, Eric ^a   Nelson, Linda ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL;

ADULT; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMENTIA; DOWN SYNDROME; DRUG EFFICACY; HUMAN; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; SCORING SYSTEM; TREATMENT OUTCOME;

ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; DOWN SYNDROME; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INDANS; MALE; MIDDLE AGED; NOOTROPIC AGENTS; PILOT PROJECTS; PIPERIDINES; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME;

EID: 0036311075     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.59.7.1133     Document Type: Article

References (16)

1. The neurology of Alzheimer's disease
2. Pathological evidence for neurotransmitter deficits in Down's syndrome of middle age
3. Antibodies from Down's syndrome patients bind to the same cholinergic neurofilament protein recognized by Alzheimer's disease antibodies
4. Alzheimer's disease: Cholinergic therapy and beyond
5. Effect of tacrine on language, praxis, and noncognitive behavioral problems in Alzheimer disease
6. Sustained cognitive improvement following treatment of Alzheimer's disease with donepezil
7. Diagnosis of dementia in individuals with intellectual disability
8. Alzheimer dementia in Down's syndrome: The relevance of cognitive ability
9. Sequence of cognitive decline in dementia in adults with Down's syndrome
10. Comparison of rating scales for the diagnosis of dementia in adults with Down's syndrome
11. Cholinergic therapy for Down's syndrome
12. Adverse effects of donepezil in treating Alzheimer's disease associated with Down's syndrome
13. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease
14. Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease
15. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease